Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Denosumab Plus PD-1 Therapy in HCC With Bone Metastases
NCT07537972Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in bone metastasis, sponsored by Tongji Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT07537972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537972.